Company news

Regenxbio Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

REGENXBIO Announces Presentations of RGX-121 at the 21st Annual WORLDSymposium 2025

January 29, 2025

REGENXBIO and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111 for MPS Diseases

January 13, 2025

AbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program

January 12, 2025

REGENXBIO initiates pivotal Phase of affinity Duchenne® trial of RGX-202 gene therapy and reports positive functional data

November 17, 2024

REGENXBIO to Host Webcast Discussing Pivotal Program and First Functional Data from the AFFINITY DUCHENNE® Trial of RGX-202

November 13, 2024

REGENXBIO Reports Third Quarter 2024 Financial Results and Recent Operational Updates

November 5, 2024

REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2024 Financial Results and Recent Operational Highlights

October 29, 2024

REGENXBIO Presents Positive Data from the Phase II Study of Subretinal ABBV-RGX-314 in Patients with Bilateral Wet AMD at AAO 2024

October 20, 2024

REGENXBIO Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting

October 17, 2024

REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines Conference

September 22, 2024

REGENXBIO Appoints Mitchell Chan as Chief Financial Officer

September 16, 2024

REGENXBIO Announces Positive Data from Pivotal Dose Level of RGX-121 Demonstrating Long-Term Systemic Effect

September 2, 2024

REGENXBIO Announces Presentation at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium

August 26, 2024

REGENXBIO to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

August 7, 2024

REGENXBIO Reports Second Quarter 2024 Financial Results and Recent Operational Highlights

July 31, 2024

REGENXBIO announces new positive data from affinity Duchenne® trial of RGX-202

July 31, 2024

REGENXBIO to Host Conference Call on August 1 to Discuss Second Quarter 2024 Financial Results and Recent Operational Highlights

July 24, 2024

REGENXBIO Announces Expansion of AFFINITY DUCHENNE® Trial to Include a New Cohort of Younger Patients

June 23, 2024

REGENXBIO Announces Successful Pre-BLA Meeting with FDA to Support Accelerated Approval Pathway for RGX-121 for the Treatment of MPS II

June 17, 2024

REGENXBIO Announces Leadership Transition

June 11, 2024

REGENXBIO to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

June 4, 2024

REGENXBIO Reports First Quarter 2024 Financial Results and Recent Operational Highlights

May 7, 2024

REGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2024 Financial Results and Recent Operational Highlights

April 30, 2024

REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

April 23, 2024

REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD

March 27, 2024

REGENXBIO to Participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy Days

March 26, 2024

REGENXBIO Announces Proposed Public Offering of Common Stock

March 5, 2024

REGENXBIO Announces Pricing of Upsized Public Offering of Common Stock and Pre-funded Warrants

March 5, 2024

REGENXBIO announces new positive initial efficacy data from affinity Duchenne® trial

March 4, 2024

REGENXBIO to Host Webcast Event to Discuss New Interim Clinical Data from the Phase I/II AFFINITY DUCHENNE® Trial

February 28, 2024

REGENXBIO Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights

February 26, 2024

REGENXBIO to Host Conference Call on February 27 to Discuss Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights

February 20, 2024

REGENXBIO Announces Pivotal Trial of RGX-121 for the Treatment of MPS II Achieves Primary Endpoint

February 6, 2024

REGENXBIO Announces Completion of Enrollment in Cohort 2 and Additional Positive Interim Data in AFFINITY DUCHENNE® Trial

February 6, 2024

REGENXBIO Announces Presentations at the 20th Annual WORLDSymposium 2024

January 30, 2024

REGENXBIO Announces Positive Interim Data from Phase II AAVIATE® Trial of ABBV-RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery

January 15, 2024

REGENXBIO Announces Presentation at the Hawaiian Eye and Retina 2024 Meeting

January 9, 2024

U.S. District Court Issues Decision on REGENXBIO and University of Pennsylvania NAV® Technology Patent Infringement Lawsuit

January 7, 2024

REGENXBIO Announces Dose Escalation in AFFINITY DUCHENNE® Trial

November 28, 2023

REGENXBIO Announces Updated Strategic Plans and Third Quarter 2023 Financial Results

November 7, 2023

REGENXBIO Presents Positive One Year Data from Phase II ALTITUDE® Trial of ABBV-RGX-314 for Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery

November 2, 2023

REGENXBIO to Host Conference Call on November 8 to Discuss Third Quarter 2023 Financial Results and Recent Operational Highlights

October 31, 2023

REGENXBIO Announces Presentations at the American Academy of Ophthalmology 2023 Annual Meeting

October 29, 2023

REGENXBIO to Participate in the Jefferies CNS/Neuro Summit

October 4, 2023

REGENXBIO Presents Interim Clinical Data from Phase I/II AFFINITY DUCHENNE™ Trial of RGX-202 at 28th Annual International Congress of the World Muscle Society

October 2, 2023

REGENXBIO Announces Presentations at the 28th Annual Congress of the World Muscle Society

September 25, 2023

Initial Clinical Data of First Pediatric CLN2 Patient Dosed with RGX-181 Presented at SSIEM Annual Symposium

August 29, 2023

REGENXBIO Announces Presentations at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2023

August 22, 2023

REGENXBIO Reports Second Quarter 2023 Financial Results and Recent Operational Highlights

August 1, 2023

REGENXBIO Announces Participation at the 2023 Wedbush PacGrow Healthcare Conference

July 31, 2023

← Newer news releases · Older news releases →

Calls

The 5 newest of 24 calls. Every call is listed under its year.

Decks

The 5 newest of 21 decks. Every deck is listed under its year.